Cargando…
ANCA-Associated Vasculitis after Moderna COVID-19 Vaccination
We experienced a case of myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis after Moderna COVID-19 vaccination. An 82-year-old woman developed pyrexia and general malaise one month after her third booster vaccine, and the symptoms persisted. Blood testing revealed i...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10125765/ https://www.ncbi.nlm.nih.gov/pubmed/37101523 http://dx.doi.org/10.1155/2023/4906876 |
_version_ | 1785030094520057856 |
---|---|
author | Gen, Shiko Iwai, Takanori Ohnari, Sayuri Nobe, Kanako Ikeda, Naofumi |
author_facet | Gen, Shiko Iwai, Takanori Ohnari, Sayuri Nobe, Kanako Ikeda, Naofumi |
author_sort | Gen, Shiko |
collection | PubMed |
description | We experienced a case of myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis after Moderna COVID-19 vaccination. An 82-year-old woman developed pyrexia and general malaise one month after her third booster vaccine, and the symptoms persisted. Blood testing revealed inflammation, a high level of MPO-ANCA, and microscopic hematuria. MPO-ANCA-associated vasculitis was diagnosed by renal biopsy. The symptoms improved with steroid therapy. Common adverse reactions to mRNA vaccines against COVID-19 include pyrexia and general malaise, but MPO-ANCA-associated vasculitis can also occur. If pyrexia, prolonged general malaise, urinary occult blood, or renal impairment is observed, the onset of MPO-ANCA-associated vasculitis should be considered. |
format | Online Article Text |
id | pubmed-10125765 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-101257652023-04-25 ANCA-Associated Vasculitis after Moderna COVID-19 Vaccination Gen, Shiko Iwai, Takanori Ohnari, Sayuri Nobe, Kanako Ikeda, Naofumi Case Rep Nephrol Case Report We experienced a case of myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis after Moderna COVID-19 vaccination. An 82-year-old woman developed pyrexia and general malaise one month after her third booster vaccine, and the symptoms persisted. Blood testing revealed inflammation, a high level of MPO-ANCA, and microscopic hematuria. MPO-ANCA-associated vasculitis was diagnosed by renal biopsy. The symptoms improved with steroid therapy. Common adverse reactions to mRNA vaccines against COVID-19 include pyrexia and general malaise, but MPO-ANCA-associated vasculitis can also occur. If pyrexia, prolonged general malaise, urinary occult blood, or renal impairment is observed, the onset of MPO-ANCA-associated vasculitis should be considered. Hindawi 2023-04-17 /pmc/articles/PMC10125765/ /pubmed/37101523 http://dx.doi.org/10.1155/2023/4906876 Text en Copyright © 2023 Shiko Gen et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Gen, Shiko Iwai, Takanori Ohnari, Sayuri Nobe, Kanako Ikeda, Naofumi ANCA-Associated Vasculitis after Moderna COVID-19 Vaccination |
title | ANCA-Associated Vasculitis after Moderna COVID-19 Vaccination |
title_full | ANCA-Associated Vasculitis after Moderna COVID-19 Vaccination |
title_fullStr | ANCA-Associated Vasculitis after Moderna COVID-19 Vaccination |
title_full_unstemmed | ANCA-Associated Vasculitis after Moderna COVID-19 Vaccination |
title_short | ANCA-Associated Vasculitis after Moderna COVID-19 Vaccination |
title_sort | anca-associated vasculitis after moderna covid-19 vaccination |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10125765/ https://www.ncbi.nlm.nih.gov/pubmed/37101523 http://dx.doi.org/10.1155/2023/4906876 |
work_keys_str_mv | AT genshiko ancaassociatedvasculitisaftermodernacovid19vaccination AT iwaitakanori ancaassociatedvasculitisaftermodernacovid19vaccination AT ohnarisayuri ancaassociatedvasculitisaftermodernacovid19vaccination AT nobekanako ancaassociatedvasculitisaftermodernacovid19vaccination AT ikedanaofumi ancaassociatedvasculitisaftermodernacovid19vaccination |